ARCHIVES

BMS Execs Knew Of Flaws In ImClone Plan For C225 Prior To $2-Billion Licensing Deal

This article is from The Cancer Letter archive.

Vol. 28 No. 25 | June 21, 2002

Download PDF Visit The Full Archive

Related Articles

DCPC BSC Committee Endorses Three Research Concepts

April 17, 1987

Importation Is Remedy of Last Resort in Effort to Obtain Generic Injectables

March 2, 2012

Avon to Support Community Programs

January 7, 1994

In Brief: Armitage Appointed to NCAB; UT Board Approves New Clinical Building for MDACC

May 19, 2000

NCAB To Hear Program Reviews, Try Again On Act Revisions

October 22, 1976

Litton Loses To PRI On Largest Frederick Contract, Competing Against Hopkins For Science Program

August 27, 1982